Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 7, 2007

Cardio³ BioSciences Licenses Cardiac Stem Cell Technology from Mayo Clinic


  • Cardio³ BioSciences and Mayo Clinic entered into a collaborative agreement related to the licensing of Mayo Clinic research, know-how, and intellectual property in the field of cardiac commitment of stem cells.

    The research, headed by André Terzic, M.D., Ph.D., and Atta Behfar at the Mayo Clinic, has focused on the guided commitment of adult as well as embryonic stem cells. The scope of the license covers heart failure of ischemic and non-ischemic origin.

    “Over one million Americans suffer a new or recurrent heart attack each year.  Despite the aggressive approaches we use to treat heart patients, no effective means are available to repair a damaged heart,” says André Terzic, M.D., Ph.D., Mayo Clinic. “Discoveries by the Mayo team open new therapeutic avenues exploiting the regenerative potential of stem cells guided toward cardiac lineage.  We are excited about translating this novel methodology into repair strategies.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »